Latin America Companion Diagnostics Market Report to 2028 - Featuring Almac, Biocartis, Danaher, GE Healthcare and Qiagen Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Latin America Companion Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

The publisher's research report insinuates that the Latin American companion diagnostics market is expected to register growth at a compound annual growth rate of 12.10% during the forecasting years 2022-2028. Mexico, Brazil, and Rest of Latin America are considered in the region.

Companies Mentioned

• Abbott Laboratories
• Almac Group
• Arup Laboratories
• Biocartis
• Biomerieux
• Danaher Corporation
• GE Healthcare
• Genomic Health
• Illumina Inc
• Myriad Genetics
• Qiagen
• Roche Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific
• Agilent

In Mexico, initiatives undertaken to reduce approval time for clinical trials are anticipated to surge the adoption of companion diagnostics devices.

For instance, the government amended various acts to accelerate clinical trials. Besides this, the Federal Commission for the Protection against Sanitary Risk is working on various aspects to decrease the hurdles faced during these trials. Moreover, it aims to increase the number of pharmaceutical companies conducting clinical trials. Thus, these factors are expected to contribute to the expansion of the companion diagnostics market.

In Rest of Latin America, countries like Argentina, Peru, Chile, and Columbia are expected to witness consistent growth over the forecast period.

As per estimates, the in-vitro and molecular diagnostics industry is expanding at a rapid pace, which is estimated to augment the companion diagnostics market's growth. In Argentina, the rising acceptance of advanced diagnostic technologies by physicians is among the major factors supporting the studied market's growth.

Key Topics Covered:

1. Latin America Companion Diagnostics Market - Summary

2. Industry Outlook

2.1. Impact of Covid-19 on the Companion Diagnostics Market

2.2. Key Insights

2.2.1. Commercial Success of Precision Medicine Treatment

2.2.2. Adoption of Predictive Biomarkers

2.2.3. Fusion of Computer Science and Biology

2.3. Porter's Five Forces Analysis

2.4. Key Buying Impact Analysis

2.4.1. Cost

2.4.2. Availability

2.4.3. Sensitivity & Specificity

2.4.4. Efficacy

2.5. Market Attractiveness Index

2.6. Vendor Scorecard

2.7. Industry Components

2.8. Regulatory Framework

2.9. Key Market Strategies

2.9.1. Acquisitions

2.9.2. Product Launches

2.9.3. Contracts & Agreements

2.10. Market Drivers

2.10.1. Increase in Incidence of Medication Reactions

2.10.2. Increasing Prevalence of Cancer Cases and Fatalities

2.10.3. Rising Prevalence of Precision Medicines

2.11. Market Challenges

2.11.1. Weak Reimbursement Framework

2.11.2. Common Cases of Leakage in Oncology Companion Diagnostics

2.12. Market Opportunity

2.12.1. Ongoing Research and Investments in Next Generation Gene-Sequencing

3. Latin America Companion Diagnostics Market Outlook - by Mechanism

3.1. In-Situ Hybridization

3.2. Polymerase Chain Reaction

3.3. Immunohistochemistry

3.4. Next Generation Sequencing

3.5. Other Mechanisms

4. Latin America Companion Diagnostics Market Outlook - by Indicator

4.1. Oncology

4.2. Neurology

4.3. Infectious Diseases

4.4. Other Indicators

5. Latin America Companion Diagnostics Market Outlook - by Consumer

5.1. Pharmaceutical and Biopharmaceutical Companies

5.2. Reference Laboratories

5.3. Other Consumers

6. Latin America Companion Diagnostics Market Outlook - by Commodity

6.1. Assay Kits and Reagents

6.2. Software and Services

7. Latin America Companion Diagnostics Market - Country Outlook

7.1. Brazil

7.2. Mexico

7.3. Rest of Latin America

8. Competitive Landscape

9. Research Methodology & Scope

For more information about this report visit https://www.researchandmarkets.com/r/o5yku7